RxDoctor Payments Data

Dora Cantu, MD

Ophthalmology · Houston, TXNPI 1194725366

Payments from drug & device makers

$1,494in general payments, 2019–2025

Across 51 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$849
  • Tarsus Pharmaceuticals, Inc.$140
  • Alcon$93
  • Sun Pharmaceutical Industries Inc.$63
  • Carl Zeiss Meditec USA, Inc.$57
  • Harrow Eye, LLC$56
  • plus $236 from 7 others

What the payments were for

  • Food & beverage$1,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,494 in reported general payments places this provider in the 40th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$398,719
Medicare patients
383
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine211$295,823
LumiganBimatoprost172$116,013
XdemvyLotilaner36$67,024
Cyclosporine71$39,800
Prednisolone Acetate576$25,049
CombiganBrimonidine Tartrate/Timolol41$18,590
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol126$17,117
Loteprednol Etabonate68$13,409
Latanoprost1,002$11,073
Dorzolamide-TimololDorzolamide/Timolol/Pf50$10,176
Brimonidine Tartrate355$6,778
Travoprost47$6,292
ErythromycinErythromycin Base457$4,110
TafluprostTafluprost/Pf15$3,471
Brinzolamide21$3,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$12$430,427424 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$140$67,02436 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$23$13,40968 claims
Bausch & Lomb Americas Inc.Vyzulta$44$3,20011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →